{"entity":{"type":"insider","cik":"0001651281","url":"/insider/0001651281","json_url":"/insider/0001651281.json","name":"SCHEIBLER LUKAS","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":26,"n_filings":24,"first":"2016-08-18","last":"2023-12-05","span_basis":"filed_date"},"name_variants":[{"name":"SCHEIBLER LUKAS","source":"filing","n_filings":24,"first_seen":"2016-08-18","last_seen":"2023-12-05"}],"transactions":[{"id":8433362,"accession":"0001127602-23-028966","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-23-028966","line_url":"/filing/0001127602-23-028966#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (Chief Research Officer)","role_mark":"O","role_mark_label":"Officer (Chief Research Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Research Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":600000.0,"total_display":"600,000.00","total_whole":"600,000","shares_owned_after":68299.0,"shares_owned_after_display":"68,299","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-01","filed_date":"2023-12-05","scope":"insider"},{"id":8603878,"accession":"0001127602-23-023845","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-023845","line_url":"/filing/0001127602-23-023845#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (Chief Research Officer)","role_mark":"O","role_mark_label":"Officer (Chief Research Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Research Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1756.0,"shares_display":"1,756","price_per_share":43.01,"price_display":"43.01","price_state":"stated","total_value":75525.56,"total_display":"75,525.56","total_whole":"75,526","shares_owned_after":68299.0,"shares_owned_after_display":"68,299","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-06","filed_date":"2023-09-07","scope":"insider"},{"id":6772641,"accession":"0001127602-22-016013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-016013","line_url":"/filing/0001127602-22-016013#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":43.0,"price_display":"43.00","price_state":"stated","total_value":430000.0,"total_display":"430,000.00","total_whole":"430,000","shares_owned_after":40358.0,"shares_owned_after_display":"40,358","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-27","filed_date":"2022-05-31","scope":"insider"},{"id":6599575,"accession":"0001127602-22-011670","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-011670","line_url":"/filing/0001127602-22-011670#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":609.0,"shares_display":"609","price_per_share":60.087,"price_display":"60.09","price_state":"stated","total_value":36592.983,"total_display":"36,592.98","total_whole":"36,593","shares_owned_after":52233.0,"shares_owned_after_display":"52,233","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-05","filed_date":"2022-04-06","scope":"insider"},{"id":6538879,"accession":"0001127602-22-011526","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001127602-22-011526","line_url":"/filing/0001127602-22-011526","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3504.0,"shares_display":"3,504","price_per_share":56.96036900684931,"price_display":"56.96","price_state":"stated","total_value":199589.133,"total_display":"199,589.13","total_whole":"199,589","shares_owned_after":53482.0,"shares_owned_after_display":"53,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-04","filed_date":"2022-04-05","scope":"insider","n_lines":3},{"id":6649662,"accession":"0001127602-22-011246","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-011246","line_url":"/filing/0001127602-22-011246#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11496.0,"shares_display":"11,496","price_per_share":55.05,"price_display":"55.05","price_state":"stated","total_value":632854.8,"total_display":"632,854.80","total_whole":"632,855","shares_owned_after":52233.0,"shares_owned_after_display":"52,233","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-01","filed_date":"2022-04-04","scope":"insider"},{"id":6598926,"accession":"0001127602-22-004908","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-22-004908","line_url":"/filing/0001127602-22-004908#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1666.0,"shares_display":"1,666","price_per_share":46.8,"price_display":"46.80","price_state":"stated","total_value":77968.8,"total_display":"77,968.80","total_whole":"77,969","shares_owned_after":51513.0,"shares_owned_after_display":"51,513","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-11","filed_date":"2022-02-14","scope":"insider"},{"id":6419627,"accession":"0001127602-22-004774","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001127602-22-004774","line_url":"/filing/0001127602-22-004774#line-3","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":500000.0,"total_display":"500,000.00","total_whole":"500,000","shares_owned_after":53179.0,"shares_owned_after_display":"53,179","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-10","filed_date":"2022-02-14","scope":"insider"},{"id":6928791,"accession":"0001127602-22-004067","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-004067","line_url":"/filing/0001127602-22-004067#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":450000.0,"total_display":"450,000.00","total_whole":"450,000","shares_owned_after":53857.0,"shares_owned_after_display":"53,857","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-08","filed_date":"2022-02-10","scope":"insider"},{"id":6598724,"accession":"0001127602-22-002804","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-22-002804","line_url":"/filing/0001127602-22-002804#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1233.0,"shares_display":"1,233","price_per_share":38.47,"price_display":"38.47","price_state":"stated","total_value":47433.51,"total_display":"47,433.51","total_whole":"47,434","shares_owned_after":53857.0,"shares_owned_after_display":"53,857","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-01","scope":"insider"},{"id":5004291,"accession":"0001127602-21-019710","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-21-019710","line_url":"/filing/0001127602-21-019710#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (CHIEF INNOVATION OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF INNOVATION OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF INNOVATION OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3417.0,"shares_display":"3,417","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":205020.0,"total_display":"205,020.00","total_whole":"205,020","shares_owned_after":26651.0,"shares_owned_after_display":"26,651","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-10","filed_date":"2021-06-11","scope":"insider"},{"id":6618982,"accession":"0000899243-18-014257","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-014257","line_url":"/filing/0000899243-18-014257#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2935.0,"shares_display":"2,935","price_per_share":20.37,"price_display":"20.37","price_state":"stated","total_value":59785.95,"total_display":"59,785.95","total_whole":"59,786","shares_owned_after":2935.0,"shares_owned_after_display":"2,935","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-24","filed_date":"2018-05-29","scope":"insider"},{"id":5332739,"accession":"0001400482-17-000072","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000072","line_url":"/filing/0001400482-17-000072#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1250.0,"shares_display":"1,250","price_per_share":6.5,"price_display":"6.50","price_state":"stated","total_value":8125.0,"total_display":"8,125.00","total_whole":"8,125","shares_owned_after":11108.0,"shares_owned_after_display":"11,108","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-17","filed_date":"2017-07-18","scope":"insider"},{"id":4096415,"accession":"0001400482-17-000066","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000066","line_url":"/filing/0001400482-17-000066#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1300.0,"shares_display":"1,300","price_per_share":6.95,"price_display":"6.95","price_state":"stated","total_value":9035.0,"total_display":"9,035.00","total_whole":"9,035","shares_owned_after":9695.0,"shares_owned_after_display":"9,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-20","filed_date":"2017-06-20","scope":"insider"},{"id":5294178,"accession":"0001400482-17-000054","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000054","line_url":"/filing/0001400482-17-000054#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1275.0,"shares_display":"1,275","price_per_share":6.15,"price_display":"6.15","price_state":"stated","total_value":7841.25,"total_display":"7,841.25","total_whole":"7,841","shares_owned_after":8331.0,"shares_owned_after_display":"8,331","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-17","filed_date":"2017-05-18","scope":"insider"},{"id":5002686,"accession":"0001400482-17-000039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000039","line_url":"/filing/0001400482-17-000039#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1320.0,"shares_display":"1,320","price_per_share":6.48,"price_display":"6.48","price_state":"stated","total_value":8553.6,"total_display":"8,553.60","total_whole":"8,554","shares_owned_after":6943.0,"shares_owned_after_display":"6,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-17","filed_date":"2017-04-17","scope":"insider"},{"id":4129991,"accession":"0001400482-17-000033","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000033","line_url":"/filing/0001400482-17-000033#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1250.0,"shares_display":"1,250","price_per_share":7.1,"price_display":"7.10","price_state":"stated","total_value":8875.0,"total_display":"8,875.00","total_whole":"8,875","shares_owned_after":5599.0,"shares_owned_after_display":"5,599","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-20","filed_date":"2017-03-20","scope":"insider"},{"id":5189742,"accession":"0001400482-17-000022","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000022","line_url":"/filing/0001400482-17-000022#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1450.0,"shares_display":"1,450","price_per_share":8.1,"price_display":"8.10","price_state":"stated","total_value":11745.0,"total_display":"11,745.00","total_whole":"11,745","shares_owned_after":4186.0,"shares_owned_after_display":"4,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-17","filed_date":"2017-02-21","scope":"insider"},{"id":5189723,"accession":"0001400482-17-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-17-000010","line_url":"/filing/0001400482-17-000010#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1475.0,"shares_display":"1,475","price_per_share":8.7,"price_display":"8.70","price_state":"stated","total_value":12832.5,"total_display":"12,832.50","total_whole":"12,833","shares_owned_after":2972.0,"shares_owned_after_display":"2,972","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-18","filed_date":"2017-01-20","scope":"insider"},{"id":2186842,"accession":"0001400482-16-000270","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-16-000270","line_url":"/filing/0001400482-16-000270#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":880.0,"shares_display":"880","price_per_share":8.18,"price_display":"8.18","price_state":"stated","total_value":7198.4,"total_display":"7,198.40","total_whole":"7,198","shares_owned_after":1784.0,"shares_owned_after_display":"1,784","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-12-22","filed_date":"2016-12-27","scope":"insider"},{"id":2759032,"accession":"0001400482-16-000263","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-16-000263","line_url":"/filing/0001400482-16-000263#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"ACUCELA INC.","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2663.0,"shares_display":"2,663","price_per_share":9.3468,"price_display":"9.35","price_state":"stated","total_value":24890.5284,"total_display":"24,890.53","total_whole":"24,891","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-21","filed_date":"2016-11-21","scope":"insider"},{"id":2613525,"accession":"0001400482-16-000261","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001400482-16-000261","line_url":"/filing/0001400482-16-000261#line-1","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"ACUCELA INC.","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1774.0,"shares_display":"1,774","price_per_share":9.4394,"price_display":"9.44","price_state":"stated","total_value":16745.4956,"total_display":"16,745.50","total_whole":"16,745","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-14","filed_date":"2016-11-15","scope":"insider"},{"id":2854144,"accession":"0001400482-16-000230","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-16-000230","line_url":"/filing/0001400482-16-000230#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"ACUCELA INC.","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2663.0,"shares_display":"2,663","price_per_share":9.5312,"price_display":"9.53","price_state":"stated","total_value":25381.5856,"total_display":"25,381.59","total_whole":"25,382","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-20","filed_date":"2016-09-20","scope":"insider"},{"id":3304017,"accession":"0001400482-16-000219","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001400482-16-000219","line_url":"/filing/0001400482-16-000219#line-2","is_derivative":false,"issuer_cik":"0001400482","issuer_name":"ACUCELA INC.","issuer_ticker":"M","issuer_name_source":null,"issuer_url":"/issuer/0001400482","owner_cik":"0001651281","owner_name":"SCHEIBLER LUKAS","owner_display_name":"SCHEIBLER LUKAS","owner_url":"/insider/0001651281","role":"Officer (EVP of Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP of Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP of Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31962.0,"shares_display":"31,962","price_per_share":10.81,"price_display":"10.81","price_state":"stated","total_value":345509.22,"total_display":"345,509.22","total_whole":"345,509","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-18","filed_date":"2016-08-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":26,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":25,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":26},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001492422","name":"Apellis Pharmaceuticals, Inc.","url":"/issuer/0001492422","role":"Officer (Chief Research Officer)","n_filings":12,"first_seen":"2018-05-29","last_seen":"2023-12-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001400482","name":"KUBOTA PHARMACEUTICAL HOLDINGS CO LTD","url":"/issuer/0001400482","role":"Officer (EVP of Research & Development)","n_filings":12,"first_seen":"2016-08-18","last_seen":"2017-07-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001651281","retrieved_at":"2026-08-26T06:01:26+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}